Table 6.
The NMA presents the impact of each intervention for adverse events
| Placebo | 0.32 (0.15,0.69) | 0.40 (0.22,0.71) | 0.24 (0.07,0.79) | 0.80 (0.26,2.42) | 0.33 (0.11,0.97) | 0.54 (0.24,1.18) | 1.00 (0.19,5.42) | 1.00 (0.02,58.05) | 0.45 (0.16,1.29) |
|---|---|---|---|---|---|---|---|---|---|
| 0.32 (0.15,0.69) | sunitinib | NA | NA | NA | NA | NA | NA | NA | NA |
| 0.40 (0.22,0.71) | 1.23 (0.48,3.20) | sorafenib | NA | NA | NA | NA | NA | NA | NA |
| 0.24 (0.07,0.79) | 0.75 (0.18,3.05) | 0.60 (0.16,2.25) | nivolumab + ipilimumab | NA | NA | NA | NA | NA | NA |
| 0.80 (0.26,2.42) | 2.46 (0.64,9.47) | 1.99 (0.57,6.96) | 3.30 (0.65,16.77) | atezolizumab | NA | NA | NA | NA | NA |
| 0.33 (0.11,0.97) | 1.02 (0.27,3.83) | 0.83 (0.24,2.81) | 1.37 (0.28,6.82) | 0.42 (0.09,1.96) | pazopanib | NA | NA | NA | NA |
| 0.54 (0.24,1.18) | 1.66 (0.55,4.96) | 1.34 (0.51,3.56) | 2.22 (0.53,9.24) | 0.67 (0.17,2.63) | 1.62 (0.42,6.15) | pembrolizumab | NA | NA | NA |
| 1.00 (0.19,5.42) | 3.11 (0.49,19.74) | 2.52 (0.42,14.92) | 4.17 (0.53,32.72) | 1.26 (0.17,9.50) | 3.03 (0.41,22.42) | 1.88 (0.29,12.06) | girentuximab | NA | NA |
| 1.00 (0.02,58.05) | 3.09 (0.05,192.80) | 2.51 (0.04,151.46) | 4.15 (0.06,285.53) | 1.26 (0.02,84.73) | 3.02 (0.05,201.79) | 1.87 (0.03,117.00) | 1.00 (0.01,80.82) | tegafur + uracil | NA |
| 0.45 (0.16,1.29) | 1.39 (0.38,5.10) | 1.12 (0.34,3.74) | 1.86 (0.38,9.11) | 0.56 (0.12,2.61) | 1.36 (0.30,6.13) | 0.84 (0.22,3.13) | 0.45 (0.06,3.26) | 0.45 (0.01,29.81) | axitinib |